Able Innovations Works to Transform Frontline Healthcare with USD $6MM in Funding

Able Innovations, a Toronto-based robotic medical device start-up, is garnering significant support for its revolutionary ALTA Platform™ with an announcement of a total raise of USD $6MM.

This represents previously unannounced venture capital and grant funding, including USD $2.5MM in non-dilutive funding.

Able Innovations is using robotics to transform processes for healthcare staff by incorporating safety and dignity into a routine procedure that affects providers and patients.

The ALTA Platform automates the demanding task of patient transfer: moving a patient from one surface to another — e.g.: from bed to stretcher. Such transfers occur frequently and require 2 or more staff to exert back-breaking effort. In a post-pandemic system that is seeing nurses burn out and facilities short-staffed, ALTA enables workers to do more with less.

Able Innovations’ founders Jayiesh Singh and Philip Chang began developing ALTA in 2018, drawing from Jay’s experience volunteering in long-term care, and Philip’s struggles with transfer as a patient himself.

“The intense effort required in patient transfer under the current standard of care is not sustainable,” says Able CEO Jayiesh Singh. “The pandemic has widened cracks in the healthcare system, and patient transfer is one of them.”

Able’s unique solution has resulted in partnerships with leading Canadian and American systems including the U.S. Veterans Health Administration (VHA), Toronto’s University Health Network (UHN), and Ottawa’s Élisabeth Bruyère Hospital.

“Able is redefining values related to patient transfers,” says Dr. Gaurav Puri, Chief of Emergency at Southlake Regional Hospital. “Able has demonstrated its commitment to a device that transfers patients safely, efficiently, and with dignity, while minimizing injuries to staff.”

Able Innovations gratefully acknowledges support of crucial investors and funders including:

Champion physicians Dr. Gaurav Puri and Dr. Andrew Vellathottam
NorthSpring Capital Partners
University of Waterloo’s incubator, Velocity, and its Health Tech Fund
Ontario Centre of Innovation’s Market Readiness Fund
Federal and provincial government grants

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Kazia has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs. The warrants will have an exercise price of $0.583 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about December 5, 2023, subject to the satisfaction of customary closing conditions.
The groundbreaking ColoSeal System™ enables minimally invasive colorectal tumor removal, eliminating the need for 2 open surgeries in today's standard of care notes Savage Medical.
Alto Neuroscience advises the funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the next 12-18 month
Micron Biomedical has received this grant from the Bill & Melinda Gates Foundation to fund mass production of needle-free vaccines utilizing Micron technology to expand the accessibility of measles-rubella vaccine in developing countries
Ann Lin, co-founder and CEO of Cromatic said, "Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas. That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy